Evidence map›Paper›PMID 40592954›Full record

ArticleScientific reports2025

Quadratic unconstrained binary optimization and constraint programming approaches for lattice-based cyclic peptide docking.

J Kyle Brubaker, Kyle E C Booth, Akihiko Arakawa, Fabian Furrer, Jayeeta Ghosh, Tsutomu Sato, Helmut G Katzgraber

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J Kyle BrubakerAmazon Advanced Solutions Lab, Seattle, WA, 98170, USA.
Kyle E C BoothAmazon Advanced Solutions Lab, Seattle, WA, 98170, USA. kybooth@amazon.com.
Akihiko ArakawaResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, 244-8602, Japan.
Fabian FurrerAmazon Advanced Solutions Lab, Seattle, WA, 98170, USA.
Jayeeta GhoshAWS Professional Services, Seattle, WA, 98170, USA.
Tsutomu SatoResearch Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Kanagawa, 244-8602, Japan.
Helmut G KatzgraberAmazon Advanced Solutions Lab, Seattle, WA, 98170, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The peptide-protein docking problem is an important problem in structural biology that facilitates rational and efficient drug design. In this work, we explore modeling and solving this problem with the quantum-amenable quadratic unconstrained binary optimization (QUBO) formalism. Our work extends recent efforts by incorporating the objectives and constraints associated with peptide cyclization and peptide-protein docking in the two-particle model on a tetrahedral lattice. We propose a "resource efficient" QUBO encoding for this problem, and baseline its performance with a novel constraint programming (CP) approach. We implement an end-to-end framework that enables the evaluation of our methods on instances from the Protein Data Bank (PDB). Our results show that the QUBO approach, using a classical simulated annealing solver, is able to find feasible conformations for problems with up to 6 peptide residues and 34 target protein residues (PDB 3WNE, 5LSO), but has trouble scaling beyond this problem size. In contrast, the CP approach can solve the largest instance in our test set, containing 11 peptide residues and 49 target protein residues (PDB 2F58). We conclude that while QUBO can be used to successfully tackle this problem, its scaling limitations and the strong performance of the CP method suggest that it may not be the best choice.

Indexed as

Molecular Docking SimulationPeptides, CyclicAlgorithmsDatabases, ProteinProtein BindingProtein ConformationProteinsPeptides, CyclicProteins

Identifiers

PMID40592954
PMCPMC12214603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.